European Association for the Study of Diabetes Annual Meeting

Healio brings you the highlights from the European Association for the Study of Diabetes Annual Meeting. Refer back to this page often for the latest news from EASD, perspectives and interviews with leading researchers and clinicians, and to review archives of past meetings.

Meeting News

Sotagliflozin effectively reduces HbA1c in type 1 diabetes

September 13, 2017
Sotagliflozin, an SGLT1 and SGLT2 inhibitor, was more effective than placebo for reducing HbA1c in adults with type 1 diabetes who were receiving…
Meeting NewsPerspective

Similar CV outcomes with pioglitazone, sulfonylureas added to metformin

September 13, 2017
The incidence of cardiovascular events decreased among adults with type 2 diabetes who received pioglitazone or a sulfonylurea as an add-on to…
Meeting News

Couples may share risks for type 2 diabetes, obesity

September 12, 2017
Among middle-aged adults, a man is more likely to develop type 2 diabetes if his wife has obesity, and both men and women are more likely to develop…
Meeting News Coverage

HbA1c lowering models predict reductions in microvascular, macrovascular complications

September 19, 2016
In adults with type 2 diabetes and known cardiovascular disease, each 1% decrease in HbA1c is associated with a relative risk reduction in…
Meeting News Coverage

Marriage halves risk for overweight in adults with type 2 diabetes

September 19, 2016
Adults with type 2 diabetes who are married and living with their spouse are 50% less likely to develop overweight vs. single adults with diabetes…
Meeting News Coverage

Exenatide, dapagliflozin combination improves glycemic control

September 19, 2016
A combination of the glucagon-like peptide-1 receptor agonist exenatide and the SGLT2 inhibitor dapagliflozin is more effective for improving…
Meeting News Coverage

Anabolic steroid use associated with impaired insulin sensitivity in men

September 19, 2016
Men who abuse or have abused anabolic androgenic steroids have lower insulin sensitivity and more visceral fat than controls, possibly mediated by…
Meeting News Coverage

Semaglutide effective for glycemic control, body weight reduction

September 16, 2016
Adults with type 2 diabetes treated with metformin experienced greater glycemic control and lost more body weight with semaglutide compared with…
Meeting News Coverage

Ertugliflozin safe, effective as add-on to metformin, sitagliptin in type 2 diabetes

September 16, 2016
Adults with type 2 diabetes prescribed metformin and sitagliptin randomly assigned the SGLT2 inhibitor ertugliflozin saw a greater decrease in HbA1c…
Meeting News Coverage

Semaglutide improves CV risk in type 2 diabetes

September 16, 2016
The glucagon-like peptide-1 receptor agonist semaglutide significantly lowers the risk for cardiovascular death, nonfatal myocardial infarction or…